natgillin/translations-raw huggingface dataset:
NA=not applicable, NE=not estimated TTP-Time to Progression CI=Confidence Interval B=bortezomib; Dex=dexamethasone
NA=ne velja za ta primer, NE=odziva ni bilo mogoče oceniti TTP–čas do napredovanja bolezni CI=interval zaupanja B=bortezomib; Dex=deksametazon
NA=not available
NP = ni podatka
NAb
n/rb
Nadir ANC (cells/l)
Najnižje število ANC (celic/l)
Nadir ANC < 500/mm3 and nadir platelets ≥ 50,000/mm3
Najnižji ANC < 500/mm3 in najnižje število trombocitov ≥ 50.000/mm3
Nadir ANC < 500/mm3 and nadir platelets ≥ 50,000/mm3
Najnižji ANC < 500/mm3 in najnižje število trombocitov  50.000 /mm3
Nadir ANC < 500/mm3 and nadir platelets ≥ 50,000/mm3
Najnižji ANC  500 /mm3 in najnižje število trombocitov  50.000 /mm3
Nadir ANC < 500/mm³ and nadir platelets ≥ 50,000/mm³
Najnižji ANC < 500/mm³ in najnižje število trombocitov ≥ 50.000/mm³
Nadir ANC <500/mm3 for > 1 week
najmanjše ANC <500/mm3 za > 1 teden
Nadir counts
Število v najnižji točki
Nadir Platelet Count (cells/l)
Najnižje število krvnih ploščic (celic/l)
Nadir platelets < 50,000 /mm3 regardless of nadir ANC
Najnižje število trombocitov < 50.000 /mm3 ne glede na najnižji ANC
Nadir platelets < 50,000 /mm3 regardless of nadir ANC
Zdravljenje lahko odložimo, da omogočimo zadosten čas za okrevanje.
Nadir platelets < 50,000/mm3 regardless of nadir ANC
Najnižje število trombocitov < 50.000/mm3 ne glede na najnižji ANC
Nadir platelets < 50,000/mm3 regardless of nadir ANC
Najnižje število trombocitov  50.000 /mm3 ne glede na najnižji ANC
Nadir platelets < 50,000/mm3 with bleedinga, regardless of nadir ANC
Najnižje število trombocitov < 50.000/mm3 s krvavitvijoa, ne glede na najnižji ANC
Nadir platelets < 50,000/mm3 with bleedinga, regardless of nadir ANC
Najnižje število trombocitov  50.000 /mm3 s krvavitvijoa, ne glede na najnižji ANC
Nadir platelets < 50,000/mm³ with bleedinga, regardless of nadir ANC
Najnižje število trombocitov < 50.000/mm³ s krvavitvijoa, ne glede na najnižji ANC
Nadir platelets <50,000 /mm3 regardless of nadir ANC
Zdravljenje lahko odložimo, da omogočimo zadosten čas za okrevanje.
Nadir platelets <50,000/mm3 with bleedinga, aregardless of nadir ANC
Najnižje število trombocitov < 50.000 /mm3 s krvavitvijoa, ne glede na najnižji ANC
nafcillin (to treat infections)
nafcilin (za zdravljenje okužb)
Naglazyme 1 mg/ml concentrate for solution for infusion
Naglazyme 1 mg/ml koncentrat za raztopino za infundiranje
Naglazyme 1 mg/ml concentrate for solution for infusion Galsulfase
Naglazyme 1 mg/ml koncentrat za raztopino za infundiranje galsulfaza
Naglazyme has been authorised under ‘exceptional circumstances’.
Zdravilo Naglazyme je bilo odobreno „v izjemnih okoliščinah“.
Naglazyme is administered under the supervision of a nurse or doctor, he or she will check that the correct dose has been given and act accordingly if necessary.
Naglazyme se daje pod nadzorom sestre ali zdravnika; eden ali drugi bo preveril, da ste prejeli pravilni odmerek in ustrezno ukrepal, če bo potrebno.
Naglazyme is supplied as a concentrate for solution for infusion.
Naglazyme je na razpolago kot koncentrat za raztopino za infundiranje.
Naglazyme should not be mixed with other medicinal products in the same infusion, except for those mentioned below.
To zdravilo se ne sme mešati z drugimi zdravili razen s tistimi, ki so navedena spodaj.
Nail discolouration; Onycholysis (G3/4: 1%)
1 %), obarvanje nohtov, oniholiza (S3/4: 1 %)
Nail discolouration; Onycholysis (G3/4: 1%)
Dermatitis, eritematozen izpuščaj (S3/4: < 1 %), obarvanje nohtov, oniholiza (S3/4: 1 %)
Nail discolouration; Onycholysis (G3/4: 1%)
obarvanje nohtov, oniholiza (S3/4: 1 %)
Nail disorder
Bolezni nohtov
Nail disorder
bolečina v hrbtu
Nail disorder
poškodbe nohtov
Nail disorder
premembe na nohtih
Nail disorder
spremembe na nohtih
Nail Disorder
žulj bolezni nohtov
nail disorder (changes to the nail such as ridges and/or splitting) multiple skin eruptions (erythema multiforme).
premembe na nohtih, kot so brazde in/ali razcepljeni nohti izpuščaji različnih oblik (multiformni eritem)
Nail disorder Erythema multiforme
bolezni nohtov multiformni eritem
Nail disorder Night sweats Dry skin Erythema Hyperhidrosis Palmar plantar erythrodysaesthesia (1.0%) (G3/4: 0.1%)d
nočno potenje suha koža eritem hiperhidroza
nail disorder; breaking of the nails (onychoclasis);
bolezen nohtov, lomljenje nohtov (onihoklaza),
nail disorders
premembe na nohtih
nail disorders
premembe na nohtih,
Nail disorders (no severe)
premembe nohtov (ne hude)
Nail disorders (no severe)
premembe nohtov (nobenih hudih)
Nail disorders (severe 0.7%);
astenija (huda 9,9 %),
Nail disorders (severe 0.8%)
spremembe nohtov (hude: 0,8 %)
Nail disorders (severe 2.6%)
Srčne bolezni
Nail disorders (severe: 0.4%);
Spremembe nohtov (hude 0,8 %)
Nail disorders including paronychia.
bolezni nohtov, vključno s paronihijo
Nail disorders such as nail bed changes, nail pain, infection and swelling of the cuticles
bolezni nohtov, kot so spremembe nohtne posteljice, bolečine v predelu nohta, okužba in oteklina obnohtne kožice
Nail disorders such as nail bed changes, nail pain, infection and swelling of the cuticles
bolezni nohtov, na primer spremembe nohtne posteljice, bolečine v predelu nohtov, okužba in oteklost kožice ob nohtih
Nail disorders, breaking of your nails
bolezni nohtov, lomljivost nohtov
Nail disorders.
premembe nohtov
Nail disorderv
Bolezni sečil
Nail infection
okužba nohtov
nail infection
okužba nohtov,
Nail or skin changes (e.g. red skin)
premembe na nohtih ali koži (npr. rdeča koža),
Nail problems
premembe nohtov
Nail problems
težave z nohti
nal nal
latnos latnos
nal product or waste material should be disposed of in accordance with local
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Naloxegol 25 mg dose in the LIR subgroup resulted in a greater improvement (change from baseline) of patient assessment of constipation symptoms (PAC-SYM) total scores compared with placebo in both studies at 12 weeks (Kodiac 4 p=0.023, Kodiac 5 p=0.002).
Odmerek 25 mg naloksegola je v podskupini LIR po 12 tednih v obeh študijah prinesel večje izboljšanje (spremembo od izhodišča) bolnikove celotne ocene simptomov zaprtosti (PAC-SYM) kot placebo (Kodiac 4 p = 0,023, Kodiac 5 p = 0,002).
Naloxegol 25 mg dose, compared with placebo, also resulted in greater improvement (change from baseline) of week 12 PAC-SYM rectal domain scores in both studies (p=0.004 and p<0.001, Kodiac 4 and 5, respectively) and for the stool domain scores in Kodiac 4 (p=0.031) and Kodiac 5 (p<0.001).
Odmerek 25 mg naloksegola je v primerjavi s placebom po 12 tednih v obeh študijah prinesel tudi večje izboljšanje (spremembo od izhodišča) ocene rektalne domene PAC-SYM (Kodiac 4 p = 0,004 in Kodiac 5 p < 0,001) in ocene domene blata (Kodiac 4 p = 0,031 in Kodiac 5 p < 0,001).
Naloxegol acts by binding to mu-opioid receptors in the GI tract targeting the underlying causes of OIC (i.e. reduced GI motility, hypertonicity and increased fluid absorption resulting from long-term opioid treatment).
Deluje z vezavo na mi-opioidne receptorje v prebavilih in je tako usmerjen na osnovni vzrok OIC (npr. zmanjšano motiliteto prebavil, hipertoničnost in večjo absorpcijo tekočine kot posledico dolgotrajnega zdravljenja z opioidi).
Naloxegol has not been studied in patients with severe hepatic impairment.
Naloksegol ni raziskan pri bolnikih s hudo okvaro jeter.
Naloxegol is a PEGylated derivative of the mu-opioid receptor antagonist naloxone.
Naloksegol je PEGiliran derivat antagonista mi-opioidnih receptorjev naloksona.
Naloxegol is a peripherally acting mu-opioid receptor antagonist with restricted access to the central nervous system (CNS).
Naloksegol je periferno delujoč antagonist mi-opioidnih receptorjev z omejenim dostopom v osrednje živčevje (CNS – Central Nervous System).
Naloxegol is not recommended in patients who are taking strong CYP3A4 inducers (e.g. carbamazepine, rifampin, St. John’s Wort) (see section 4.5).
Naloksegol ni priporočljiv za bolnike, ki jemljejo močne zaviralce CYP3A4 (npr. karbamazepin, rifampin, šentjanževko) (glejte poglavje 4.5).
Naloxegol was found to have no effect on fertility of male and female rats at oral doses up to 1,000 mg/kg per day (greater than 1,000 times the human therapeutic exposure (AUC) at the recommended human dose of 25 mg/day).
Ugotovljeno je, da naloksegol ne vpliva na plodnost podganjih samcev in samic pri peroralnih odmerkih do 1.000 mg/kg na dan (več kot 1.000-kratna terapevtska izpostavljenost pri človeku (AUC) ob priporočenem odmerku za človeka 25 mg/dan).
Naloxegol was not studied in the clinical trial programme in patients who had a recent history of myocardial infarction within 6 months, symptomatic congestive heart failure, overt cardiovascular (CV) disease or patients with a QT interval of  500 msec.
Naloksegol ni bil raziskan v programu kliničnih preskušanj pri bolnikih z anamnezo nedavnega miokardnega infarkta v zadnjih 6 mesecih, simptomatskega kongestivnega srčnega popuščanja, manifestne srčno-žilne bolezni ali pri bolnikih s QT intervalom ≥ 500 msec.
Naloxone is an antagonist at -opioid receptors.
Nalokson je antagonist na ravni -opioidnih receptorjev.
Naloxone:
nalokson:
Naloxone: AUC: ↓ 28%
nalokson: AUC: ↓ 28
nalr nalr
Lestvica na gumbu
Naltrexone (100 mg/kg/day, approximately 30 times the dose of naltrexone in naltrexone/bupropion on a mg/m2 basis) caused a significant increase in pseudo-pregnancy in the rat.
Uporaba naltreksona (100 mg/kg/dan, približno 30-kratnik odmerka naltreksona v obliki kombinacije naltrekson/bupropion po merilu mg/m2) je povzročila znatno povečanje pogostnosti namišljene brejosti pri podganah.
Naltrexone / bupropion contains bupropion, a dopamine and norepinephrine re-uptake inhibitor that is similar to some active substances used for the treatment of depression.
Kombinacija naltrekson/bupropion vsebuje bupropion, zaviralec dopamina in ponovnega privzema noradrenalina, ki je podoben nekaterim učinkovinam, ki se uporabljajo za zdravljenje depresije.
Naltrexone / bupropion has minor influence on the ability to drive and use machines.
Kombinacija naltrekson/bupropion ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Naltrexone / bupropion has not been evaluated in subjects with hepatic impairment.
Kombinacije naltrekson/bupropion niso preizkušali pri preiskovancih z jetrno okvaro.
Naltrexone / bupropion has not been studied in conjunction with alpha-adrenergic blockers or clonidine.
Kombinacije naltrekson/bupropion niso preučevali v povezavi z alfaadrenergičnimi antagonisti ali klonidinom.
Naltrexone / bupropion increased metoprolol AUC and Cmax by approximately 4- and 2-fold, respectively, relative to metoprolol alone.
Zaradi naltreksona/bupropiona sta se vrednosti AUC in Cmax za metoprolol povečali približno 4- oziroma 2-kratno glede na samostojno uporabo metoprolola.
Naltrexone / bupropion is contraindicated in endstage renal failure or patients with severe renal impairment, and is not recommended in patients with moderate renal impairment.
Kombinacija naltrekson/bupropion je kontraindicirana pri bolnikih s končno odpovedjo ledvic ali hudo ledvično okvaro, pri bolnikih z zmerno ledvično okvaro pa se ne priporoča.
Naltrexone / bupropion is contraindicated in patients with central nervous system tumour, severe hepatic impairment, current or previous diagnosis of bulimia or anorexia nervosa, or withdrawal from sedatives (see section 4.3).
Kombinacija naltrekson/bupropion je kontraindicirana pri bolnikih s tumorjem centralnega živčnega sistema ali hudo jetrno okvaro, pri bolnikih, ki imajo trenutno ali so imeli v preteklosti diagnozo bulimije ali anoreksije nervoze, ali bolnikih, ki prestajajo odtegnitev pomirjeval (glejte poglavje 4.3).
Naltrexone / bupropion is contraindicated in patients with endstage renal failure or severe renal impairment, and is not recommended in patients with moderate renal impairment (see sections 4.3, 4.4, 4.8 and 5.2).
Kombinacija naltrekson/bupropion je kontraindicirana pri bolnikih s končno odpovedjo ledvic ali hudo ledvično okvaro, pri bolnikih z zmerno ledvično okvaro pa se ne priporoča (glejte poglavja 4.3, 4.4, in 5.2).
Naltrexone / bupropion is contraindicated in patients with severe hepatic impairment and is not recommended in patients with mild or moderate hepatic impairment.
Kombinacija naltrekson/bupropion je kontraindicirana pri bolnikih s hudo jetrno okvaro, pri bolnikih z blago ali zmerno jetrno okvaro pa se ne priporoča.
Naltrexone / bupropion is contraindicated in patients with severe hepatic impairment, and not recommended in patients with mild or moderate hepatic impairment (see sections 4.2, 4.8, and 5.2).
Kombinacija naltrekson/bupropion je kontraindicirana pri bolnikih s hudo jetrno okvaro, pri bolnikih z blago ali zmerno jetrno okvaro pa se ne priporoča (glejte poglavja 4.2, 4.8 in 5.2).
Naltrexone / bupropion is not recommended in patients with mild or moderate hepatic impairment.
Kombinacija naltrekson/bupropion se ne priporoča pri bolnikih z blago ali zmerno jetrno okvaro.
Naltrexone / bupropion must not be administered to patients receiving chronic opiate therapy (see section 4.3).
Kombinacija naltrekson/bupropion se ne sme uporabljati pri bolnikih, ki so vključeni v kronično zdravljenje z opiati (glejte poglavje 4.3).
Naltrexone / bupropion should preferably be taken with food, as it is known that both naltrexone and bupropion plasma concentrations are increased with food and the safety and efficacy data from clinical trials is based on dosing with food.
Priporoča se uporaba naltreksona/bupropiona skupaj s hrano, saj je znano, da se plazemska koncentracija naltreksona in bupropiona poveča s hrano, podatki iz kliničnih preskušanj o varnosti in učinkovitosti pa temeljijo na odmerjanju skupaj s hrano.
Naltrexone and bupropion and their metabolites are excreted in human milk.
Naltrekson in bupropion ter njuni presnovki se izločajo v materino mleko.
Naltrexone and bupropion are known to be substantially excreted by the kidney, and the risk of adverse reactions to naltrexone / bupropion may be greater in patients with impaired renal function, a condition that is more common in elderly individuals.
Znano je, da se naltrekson in bupropion v glavnem izločata skozi ledvice, tveganje glede neželenih učinkov pri naltreksonu/bupropionu pa je verjetno večje pri bolnikih z okvarjeno ledvično funkcijo, torej pri bolezni, ki je pogostejša pri starejših osebah.
Naltrexone and bupropion are well absorbed from the gastrointestinal tract (>90% absorbed), however, naltrexone has a significant first pass effect thereby limiting systemic bioavailablity, with only 5-6% reaching the systemic circulation intact.
Naltrekson in bupropion se iz prebavil dobro absorbirata (>90-odstotna absorpcija), vendar ima naltrekson izrazit učinek prvega prehoda, zato je sistemska biološka uporabnost omejena, saj le v 5– 6 % doseže sistemski krvni obtok v nespremenjeni obliki.
Naltrexone and nalmefene (drugs used to treat addiction disorders) may prevent the therapeutic effects of Suboxone.
Naltrekson in nalmefen (zdravili za zdravljenje odvisnosti) lahko preprečita zdravilne učinke zdravila Suboxone.
naltrexone and nalmefene are opioid antagonists that can block the pharmacological effects of buprenorphine.
Naltrekson in nalmefen sta opioidna antagonista, ki lahko blokirata farmakološke učinke buprenorfina.
Naltrexone hydrochloride has the capacity to cause hepatocellular injury when given in excessive doses (300 mg/day or approximately 10 times the recommended dose of naltrexone / bupropion).
Naltreksonijev klorid lahko, če se daje v prevelikih odmerkih (300 mg/dan ali približno 10-kratnik priporočenega odmerka naltreksona/bupropiona), povzroči okvaro jetrnih celic.
Naltrexone was negative in the following in vitro genotoxicity studies: bacterial reverse mutation assay (Ames test), the heritable translocation assay, CHO cell sister chromatid exchange assay, and the mouse lymphoma gene mutation assay.
Genotoksičnost:Naltrekson je imel negativne rezultate pri naslednjih in vitro študijah genotoksičnosti: preskus bakterijske reverzne mutacije (Amesov test), preskus dedne translokacije, preskus izmenjave med sestrskima kromatidama v celicah CHO in preskus genske mutacije mišjega limfoma.
name
40000
name
ime)
name
pakiranja
NAME AND ADDRESS O F THE MARKETING AUTHO RISATIO N HO LDER
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
NAME AND ADDRESS OF MARKETING AUTHORISATION HOLDER
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Name and address of the manufacture(s) responsible for batch release
Ime in naslov izdelovalca (izdelovalcev) zdravila, odgovornega (odgovornih) za sprostitev serije
Name and address of the manufacture(s) responsible for batch release
Ime in naslov izdelovalca, odgovornega za sproščanje serij
Name and address of the manufacturer of the biological active substance
Ime in naslov izdelovalc biološke zdravilne učinkovine
Name and address of the manufacturer of the biological active substance
Ime in naslov izdelovalca biološke zdravilne učinkovin
Name and address of the manufacturer of the biological active substance
Ime in naslov izdelovalca biološke zdravilne učinkovine (zdravilnih učinkovin)
Name and address of the manufacturer of the biological active substance
Ime in naslov izdelovalca biološke zdravilne učinkovine SICOR Biotech UAB
Name and address of the manufacturer of the biological active substance
Ime in naslov izdelovalca biološke zdravilne učinkovine.
Name and address of the manufacturer of the biological active substance and the manufacturer responsible for batch release:
Ime in naslov izdelovalca biološke zdravilne učinkovine in izdelovalca zdravila, odgovornega za sprostitev serije:
Name and address of the manufacturer of the biological active substance and the manufacturer responsible for batch release:
Ime in naslov izdelovalca biološke zdravilne učinkovine in izdelovalca, odgovornega za sproščanje serij
Name and address of the manufacturer of the biological active substance Bayer HealthCare LLC
Ime in naslov izdelovalca biološke zdravilne učinkovine (učinkovin)
Name and address of the manufacturer of the biological active substance Bio Products Laboratory Limited
Ime in naslov izdelovalca biološke zdravilne učinkovine Bio Products Laboratory Limited
Name and address of the manufacturer of the biological active substance Biogen (Denmark) Manufacturing ApS
Ime in naslov izdelovalca biološke učinkovine
Name and address of the manufacturer of the biological active substance Biogen (Denmark) Manufacturing ApS
Ime in naslov izdelovalca biološke zdravilne učinkovine Biogen (Denmark) Manufacturing ApS
Name and address of the manufacturer of the biological active substance Biogen IDEC, Inc.
Ime in naslov izdelovalca biološke zdravilne učinkovine Biogen IDEC, Inc.
Name and address of the manufacturer of the biological active substance Boehringer Ingelheim Vetmedica Inc.
Ime in naslov izdelovalca biološke zdravilne učinkovine Boehringer Ingelheim Vetmedica Inc.
Name and address of the manufacturer of the biological active substance Gentium S.r.l.
Ime in naslov izdelovalca biološke zdravilne učinkovine Gentium S.r.l.
Name and address of the manufacturer of the biological active substance GlaxoSmithKline LLC
Ime in naslov izdelovalca biološke zdravilne učinkovine
Name and address of the manufacturer of the biological active substance Holostem Terapie Avanzate S.R.L.
Ime in naslov izdelovalca biološke zdravilne učinkovine Holostem Terapie Avanzate S.R.L.
Name and address of the manufacturer of the biological active substance Intervet International
Ime in naslov izdelovalca biološke zdravilne učinkovine (zdravilnih učinkovin) Intervet International
Name and address of the manufacturer of the biological active substance Intervet International B.V.
Ime in naslov izdelovalca biološke aktivne učinkovine Intervet International B.V.
Name and address of the manufacturer of the biological active substance MolMed SpA
Ime in naslov izdelovalca biološke učinkovine MolMed SpA
Name and address of the manufacturer of the biological active substance MolMed SpA
Ime in naslov izdelovalca biološke zdravilne učinkovine MolMed SpA
Name and address of the manufacturer of the biological active substance Novo Nordisk A/S Novo Nordisk A/S
Ime in naslov izdelovalca biološke zdravilne ucinkovine Novo Nordisk A/S Novo Nordisk A/S
Name and address of the manufacturer of the biological active substance Sandoz GmbH
Ime in naslov izdelovalca biološke zdravilne učinkovine Sandoz GmbH
Name and address of the manufacturer of the biological active substance United Therapeutics Corporation
Ime in naslov izdelovalca biološke zdravilne učinkovine United Therapeutics Corporation
Name and address of the manufacturer of the biological active substance Wacker Biotech GmbH‌
Ime in naslov izdelovalca biološke zdravilne učinkovine Wacker Biotech GmbH
Name and address of the manufacturer of the biological active substance Zoetis Manufacturing & Research Spain, S.L.
Ime in naslov izdelovalca biološke zdravilne učinkovine Zoetis Manufacturing & Research Spain, S.L.
Name and address of the manufacturer of the biological active substance(s): Zoetis Manufacturing & Research Spain, S.L.
Ime in naslov izdelovalca(izdelovalcev) biološke zdravilne učinkovine (zdravilnih učinkovin) Zoetis Manufacturing & Research Spain, S.L.
Name and address of the manufacturer of the biological active substance(s)‌
Ime in naslov izdelovalca(izdelovalcev) biološke zdravilne učinkovine (zdravilnih učinkovin).
Name and address of the manufacturer of the biological active substance:
Ime in naslov izdelovalca biološke zdravilne učinkovine
Name and address of the manufacturer of the biological active substance: Biogen Inc
Ime in naslov izdelovalca biološke zdravilne učinkovine: Biogen Inc
Name and address of the manufacturer of the biological active substances
Ime in naslov izdelovalca bioloških zdravilnih učinkovin
Name and address of the manufacturer of the biological active substances
Ime in naslov izdelovalca(izdelovalcev) biološke zdravilne učinkovine (zdravilnih učinkovin)
Name and address of the manufacturer of the biological active substances
Ime in naslov izdelovalca(izdelovalcev) biološke zdravilne učinkovine (zdravilnih učinkovin):
Name and address of the manufacturer of the biological active substances
Ime in naslov izdelovalcev biološke zdravilne učinkovine
Name and address of the manufacturer of the biological active substances
Ime in naslov izdelovalcev bioloških zdravilnih učinkovin
Name and address of the manufacturer of the biological active substance‌
Ime in naslov izdelovalca biološke zdravilne učinkovine
Name and address of the manufacturer of the biological active substance‌‌
Ime in naslov izdelovalca biološke zdravilne učinkovine
Name and address of the manufacturer responsible for batch release
I0BU me in naslov izdelovalca, odgovornega za sproščanje serije
Name and address of the manufacturer responsible for batch release
Ime in naslov (izdelovalcev), (odgovornih) za sproščanje serij
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca biološke zdravilne učinkovine
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca odgovornega za sprostitev serije:
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca zdravilaodgovornega za sprostitev serije
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca zdravilnih učinkovin
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca(izdelovalcev) zdravila, odgovornega (odgovornih) za sprostitev serije Zoetis Belgium SA
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca(izdelovalcev) zdravila, odgovornega(odgovornih) za sprostitev serije
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca, ki je odgovoren za sprostitev serije
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca, odgovornega za sproščanj serij
Name and address of the manufacturer responsible for batch release
Ime in naslov izdelovalca, odgovornega za sproščanje seri